Product
risankizumab
Aliases
ABBV-066, ABBV-066 BI 655066, BI 655066, Skyrizi
Name
Skyrizi
INN Name
Risankizumab-rzaa
FDA Approved
Yes
3 clinical trials
1 organization
2 indications
1 document
Indication
PsoriasisIndication
Ulcerative ColitisClinical trial
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS)Status: Completed, Estimated PCD: 2023-11-29
Clinical trial
A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque PsoriasisStatus: Completed, Estimated PCD: 2021-11-26
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative ColitisStatus: Active (not recruiting), Estimated PCD: 2028-09-25
Document
DailyMed Label: SkyriziOrganization
AbbVie Inc.